• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接受术前化疗的乳腺癌患者生活质量评分的预后价值。

Prognostic value of quality-of-life scores in patients with breast cancer undergoing preoperative chemotherapy.

机构信息

Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan.

出版信息

BJS Open. 2018 Nov 26;3(1):38-47. doi: 10.1002/bjs5.50108. eCollection 2019 Feb.

DOI:10.1002/bjs5.50108
PMID:30734014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6354182/
Abstract

BACKGROUND

Recently, evaluation of quality of life (QOL) has been recognized as a significant outcome measure in the treatment of several cancers. In this study, the Anti-Cancer Drugs-Breast (ACD-B) QOL score was used to assess disease-specific survival in women with breast cancer undergoing preoperative chemotherapy (POC).

METHODS

QOL-ACD-B scores were evaluated before and after POC. The cut-off value of QOL-ACD-B contributing to events such as relapse or death was calculated by receiver operating characteristic (ROC) curve analysis.

RESULTS

In 300 women with breast cancer treated with POC, QOL was significantly reduced ( < 0·001). A high QOL-ACD-B score before POC was an independent factor in the multivariable analysis of overall survival (hazard ratio 0·26, 95 per cent c.i. 0·04 to 0·96).

CONCLUSION

Evaluation by QOL-ACD-B before POC may be useful to predict the prognosis of patients with breast cancer undergoing POC.

摘要

背景

最近，生活质量（QOL）的评估已被认为是治疗多种癌症的重要结果衡量标准。在这项研究中，使用抗癌症药物 - 乳房（ACD-B）QOL 评分来评估接受术前化疗（POC）的乳腺癌女性的疾病特异性生存。

方法

在 POC 前后评估 QOL-ACD-B 评分。通过接收者操作特征（ROC）曲线分析计算 QOL-ACD-B 评分的截止值，该值有助于复发或死亡等事件发生。

结果

在接受 POC 治疗的 300 名乳腺癌女性中，QOL 显著降低（<0·001）。POC 前的高 QOL-ACD-B 评分是多变量分析中总体生存的独立因素（风险比 0·26，95%置信区间 0·04 至 0·96）。

结论

在 POC 之前进行 QOL-ACD-B 评估可能有助于预测接受 POC 的乳腺癌患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b42/6354182/c61cd9d379c9/BJS5-3-38-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b42/6354182/a63db62d7156/BJS5-3-38-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b42/6354182/c61cd9d379c9/BJS5-3-38-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b42/6354182/a63db62d7156/BJS5-3-38-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b42/6354182/c61cd9d379c9/BJS5-3-38-g002.jpg

相似文献

1
Prognostic value of quality-of-life scores in patients with breast cancer undergoing preoperative chemotherapy.接受术前化疗的乳腺癌患者生活质量评分的预后价值。
BJS Open. 2018 Nov 26;3(1):38-47. doi: 10.1002/bjs5.50108. eCollection 2019 Feb.
2
Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer.用于乳腺癌术前化疗的生活质量（QOL-ACD-BP）的新型评估量表。
J Cancer Res Clin Oncol. 2018 Aug;144(8):1547-1559. doi: 10.1007/s00432-018-2670-0. Epub 2018 May 19.
3
Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.Ki-67作为新辅助化疗治疗的乳腺癌患者中一个存在争议的预测和预后标志物。
Diagn Pathol. 2017 Feb 21;12(1):20. doi: 10.1186/s13000-017-0608-5.
4
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.新辅助化疗治疗的Ⅱ/Ⅲ期乳腺癌腋窝淋巴结比率的临床意义
Breast Cancer Res Treat. 2009 Jul;116(1):153-60. doi: 10.1007/s10549-008-0160-9. Epub 2008 Sep 12.
5
Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.新辅助化疗治疗可手术乳腺癌的预后因素：对残余疾病的量化研究
Oncology. 2015;88(5):261-72. doi: 10.1159/000368557. Epub 2015 Jan 8.
6
Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.接受AC方案与CMF方案化疗的腋窝淋巴结阴性、雌激素受体阴性乳腺癌患者的健康相关生活质量：美国国家外科辅助乳腺和肠道项目B-23的研究结果
Breast Cancer Res Treat. 2004 Jul;86(2):153-64. doi: 10.1023/B:BREA.0000032983.87966.4e.
7
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.21 基因复发评分用于辅助化疗加内分泌治疗后的预后和紫杉烷获益预测：来自 NSABP B-28/NRG 肿瘤学的结果。
Breast Cancer Res Treat. 2018 Feb;168(1):69-77. doi: 10.1007/s10549-017-4550-8. Epub 2017 Nov 11.
8
Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.局部进展期乳腺癌患者在原发性全身治疗前播散肿瘤细胞的检测。
Breast. 2013 Oct;22(5):908-13. doi: 10.1016/j.breast.2013.04.014. Epub 2013 May 15.
9
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.乳腺癌患者新辅助化疗反应的独立预后指标——治疗前中性粒细胞与淋巴细胞比值的回顾性研究
BMC Cancer. 2016 May 19;16:320. doi: 10.1186/s12885-016-2352-8.
10
[Prognostic Analysis of Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy Using QOL-ACD].[使用QOL-ACD对接受新辅助化疗的乳腺癌患者进行预后分析]
Gan To Kagaku Ryoho. 2017 Nov;44(12):1092-1094.

引用本文的文献

1
Exploratory outcomes of the DHA WIN randomized controlled trial: Supplementing women with docosahexaenoic acid did not reduce the impact of neoadjuvant breast cancer chemotherapy on quality of life or exercise behaviour.DHA WIN随机对照试验的探索性结果：给女性补充二十二碳六烯酸并不能减轻新辅助乳腺癌化疗对生活质量或运动行为的影响。
PLoS One. 2025 May 2;20(5):e0322178. doi: 10.1371/journal.pone.0322178. eCollection 2025.
2
Health-Related Quality of Life and Disease Acceptance Among Women with Breast Cancer Pre- and Post-Neoadjuvant Chemotherapy.新辅助化疗前后乳腺癌女性的健康相关生活质量和疾病接受度
Cancers (Basel). 2025 Feb 2;17(3):497. doi: 10.3390/cancers17030497.
3

本文引用的文献

1
Health Related Quality of Life (HRQoL) among Breast Cancer Patients Receiving Chemotherapy in Hospital Melaka: Single Centre Experience.马六甲医院接受化疗的乳腺癌患者的健康相关生活质量：单中心经验
Asian Pac J Cancer Prev. 2016 Dec 1;17(12):5121-5126. doi: 10.22034/APJCP.2016.17.12.5121.
2
Qualitative research on the Belgian Cancer Rehabilitation Evaluation System (CARES): An evaluation of the content validity and feasibility.对比利时癌症康复评估系统（CARES）的定性研究：内容效度与可行性评估
J Eval Clin Pract. 2017 Jun;23(3):599-607. doi: 10.1111/jep.12681. Epub 2017 Jan 23.
3
Validation of the flemish CARES, a quality of life and needs assessment tool for cancer care.
Psychological distress and coping strategies in breast cancer patients under neoadjuvant therapy: A systematic review.
新辅助治疗下乳腺癌患者的心理困扰及应对策略：系统评价。
Womens Health (Lond). 2024 Jan-Dec;20:17455057241276232. doi: 10.1177/17455057241276232.
4
The quality of life assessment of breast cancer patients.乳腺癌患者的生活质量评估。
Breast Dis. 2024;43(1):173-185. doi: 10.3233/BD-249008.
5
Global quality of life and mortality risk in patients with cancer: a systematic review and meta-analysis.癌症患者的全球生活质量和死亡风险：系统评价和荟萃分析。
Qual Life Res. 2024 Oct;33(10):2631-2643. doi: 10.1007/s11136-024-03691-3. Epub 2024 May 29.
6
Association between quality of life and mortality risk in patients with breast cancer: a systematic review and meta-analysis.乳腺癌患者生活质量与死亡风险的相关性：系统评价和荟萃分析。
Breast Cancer. 2024 Jul;31(4):552-561. doi: 10.1007/s12282-024-01581-7. Epub 2024 Apr 9.
7
Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review.新辅助化疗的乳腺癌患者生活质量的系统评价。
BMJ Open. 2022 Nov 18;12(11):e061967. doi: 10.1136/bmjopen-2022-061967.
8
Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial.常规评估健康相关生活质量并结合治疗信息对非转移性乳腺癌患者内分泌治疗依从性的影响：一项随机对照试验方案。
Trials. 2020 Jun 16;21(1):527. doi: 10.1186/s13063-020-04397-w.
9
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).一项 II 期、多中心、随机试验的生活质量结果，包括神经病变相关量表，该试验比较了艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为 HER2 阴性转移性乳腺癌一线化疗：韩国癌症研究组试验（KCSG BR13-11）。
Cancer Commun (Lond). 2019 May 28;39(1):29. doi: 10.1186/s40880-019-0375-7.
验证佛兰芒CARES，一种癌症护理生活质量和需求评估工具。
BMC Cancer. 2016 Aug 30;16(1):696. doi: 10.1186/s12885-016-2728-9.
4
Partial mastectomy using manual blunt dissection (MBD) in early breast cancer.早期乳腺癌采用手法钝性分离（MBD）进行保乳手术。
BMC Surg. 2015 Oct 22;15:117. doi: 10.1186/s12893-015-0102-5.
5
Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors.在常规癌症临床实践中使用患者报告结局的情况：对使用情况、对健康结局的影响以及实施因素的范围综述。
Ann Oncol. 2015 Sep;26(9):1846-1858. doi: 10.1093/annonc/mdv181. Epub 2015 Apr 17.
6
Postoperative courses of breast reconstruction using inferior adipofascial tissue repair.使用下腹部脂肪筋膜组织修复进行乳房重建的术后过程。
Breast Cancer. 2015 Nov;22(6):570-7. doi: 10.1007/s12282-014-0522-6. Epub 2014 Jun 13.
7
Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer.FEC 100方案新辅助化疗后序贯每周紫杉醇治疗可手术乳腺癌的疗效及可行性
Oncol Lett. 2012 Oct;4(4):612-616. doi: 10.3892/ol.2012.801. Epub 2012 Jul 13.
8
Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.自我报告的健康相关生活质量是晚期乳腺癌女性化疗治疗获益和毒性的独立预测因素。
Br J Cancer. 2010 Apr 27;102(9):1341-7. doi: 10.1038/sj.bjc.6605649. Epub 2010 Apr 13.
9
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
10
The prognostic significance of patient-reported outcomes in cancer clinical trials.患者报告结局在癌症临床试验中的预后意义。
J Clin Oncol. 2008 Mar 10;26(8):1355-63. doi: 10.1200/JCO.2007.13.3439. Epub 2008 Jan 28.